Precemtabart tocentecan could soon become the industry's most advanced anti-CEACAM5 ADC.
ApexOnco Front Page
Recent articles
The company pays $2.5bn for Day One and its approved drug Ojemda.
The company will no longer initiate a head-to-head trial of safusidenib against Voranigo.
Blackstone follows Abingworth, but why?
Pfizer cans PF-08046045, but keeps PF-08046044 for now.
Bristol will advance the newest pivotal trials, in first-line colorectal and gastric cancers.
As tinkering with HLA matching continues, is nearly as good as Breyanzi good enough?
But the extensively curated dataset covering its anti-PD-L1 ADC raises more questions.
